TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01068925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 1. GSK1349572 QD x 5 days~2. TPV/RTV 500/200mg BID x 7 days~3. GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days
Study: NCT00002951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyurea

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03875989

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior colporraphy
Description: It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vaginal patch plastron
Description: It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.
Study: NCT04008758

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Evaluate participant's lung condition using ultrasound. Using lung ultrasound scoring, more than 1 point needs recruitment maneuver
Study: NCT05373303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Erythropoietin Alpha
Description: This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Erythropoietin Alpha
Description: This study consisted of a screening period (4 weeks), titration period (4\~8 weeks) baseline evaluation period (4 weeks), maintenance period (24 weeks), and 4 weeks for the evaluation period. Patients who were eligible in the screening period underwent the titration period. The reference product at an individualized dose 3 times a week through intravenous injection was given and the hemoglobin (Hb) level of the subject was controlled to reach the target range of 10-12 g/dL in the titration period. In the maintenance period, the subjects were randomized and administered with reference product or test product that was done with the same doses regimen during the titration period through intravenous injection
Study: NCT02945150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination)
Description: Elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) treatment for Hepatitis C virus (HCV)-naive recipients who receive a kidney transplant from a deceased, HCV-infected donor~Subjects receive first dose on-call to operating room, and continue daily for 12 weeks. Treatment length is extended to 16 weeks and ribavirin (daily dose 1000 mg for those \<75 kg and 1200 mg for those ≥75 kg) if subject receives a kidney from a donor who is infected with HCV containing resistance-associated variants (RAV).
Study: NCT01357577

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for PTSD
Description: The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
Study: NCT02651051

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein
Description: 20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: High Fat Breakfast Meal
Description: A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Fat Breakfast Meal
Description: A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
Study: NCT03786939

Intervention type: PROCEDURE
Group type: OTHER
Intervention: On-pump CABG.
Description: On-pump coronary artery bypass grafting.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Off-pump CABG.
Description: Off-pump coronary artery bypass grafting.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pump-assisted CABG.
Description: Pump-assisted CABG.
Study: NCT01643954

Intervention type: PROCEDURE
Group type: OTHER
Intervention: robotic radical prostatectomy
Description: robotic assisted surgery
Study: NCT03617965

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count
Description: All patients who are admitted to the intensive care unit of this hospital and meet the inclusion criteria will be followed for 90 days. There will be a complete review of the file that includes the entire hospitalization, in order to collect demographic information, clinical, laboratory reports, and imaging reports among others. Patients who are transferred to other units due to clinical improvement will be followed peripherally by the internal medicine department and the patients who are released due to clinical improvement will be contacted via telephone or in their next outpatient consultation with an internist.
Study: NCT02790957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Single injection of 0.24 mg/kg Plerixafor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single injection of an equal volume of NaCl solution
Study: NCT02946632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple combination therapy
Description: Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stepwise add-on therapy
Description: metformin -\> glimepirde -\> sitagliptin
Study: NCT01636479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR405838
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT02883530

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.

Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1-2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
Study: NCT01749540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luspatercept
Description: subcutaneous injection
Study: NCT01807923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Plus Ivacaftor Combination
Description: Fixed dose combination tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablet
Study: NCT01449318

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Thermal Sensory Analyzer (Senselab)
Description: Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.~To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.~To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C).
Study: NCT01920945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: 155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
Study: NCT02403622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Preparation
Description: Frozen processed human fecal material for treating recurrent Clostridium difficile infections.
Study: NCT00890929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
Study: NCT04231136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Description: Tegoprazan 50 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EAPA115
Description: EAPA115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RAPA115
Description: RAPA115
Study: NCT03666663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Nasal application using the Sphenocath device- cleared by FDA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Nasal application using the Sphenocath device- cleared by FDA
Study: NCT02670681

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 8 week of aerobic exercise training in different intensities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 8 week of aerobic exercise training in different intensities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise Training
Description: 8 week of aerobic exercise training in different intensities.
Study: NCT02515578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced practice transformation support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice transformation support
Study: NCT02612740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Deproteinized bovine bone
Description: cyst removal followed by heterologous bone grafting

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: granules of deproteinized bovine bone (Bio-Oss)
Study: NCT04465097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: Tucidinostat: 30 mg BIW (Monday and Thursday) from week 3 to week 26

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane: 25 mg QD from week 1 to week 26.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression
Description: If the patient is premenopausal, leuprorelin 3.75mg or goserelin 3.6 mg will be injected every 28 days.
Study: NCT03475810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Patients will wear virtual reality glasses and start watching 3 D video after confirmation of adequate motor and sensorial block.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 1-2 mg midazolam will be administered before spinal punction performed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: 1-2 mg midazolam will be administered before spinal punction performed.
Study: NCT05217303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 capsule administered orally twice daily (BID) in a 21-day treatment cycle
Study: NCT03836807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKITASK®
Description: A single oral dose of OKITASK® 40 mg was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen). The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of matching Placebo was administered to patients within 3 hours after extraction of a molar tooth (VAS ≥ 30 mm). Each patient received one sachet that contained Placebo. The content of the entire sachet was placed on the patient's tongue and swallowed. A glass of water was immediately administered after the intake of the study drug in order to rinse mouth for all subjects.
Study: NCT01367964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenocorticotropin hormone
Description: ACTH 16 units intramuscular injection once daily for 2 weeks
Study: NCT02663284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5%
Description: Ropivacaine is used to performed the perineural block
Study: NCT01348386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxide Potassium
Description: Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxide Potassium
Description: Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04048980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARExDEM
Description: CARExDEM is an educational program addressed to nurses working in traumatology units and looking after patients with dementia. This intervention pretends to provide strategies to nurses for cognitive impairment management in acute hospital settings, to raise awareness about personalized care in dementia and to improve continuity of care in acute situations in PwD. Training sessions will be held to inform and train nurses about care of PwD and their caregivers by the research team in each hospital.
Study: NCT01984944

Intervention type: OTHER
Group type: OTHER
Intervention: Autistic functional exploration
Description: * 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer

Intervention type: OTHER
Group type: OTHER
Intervention: Control functional exploration
Description: * 50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer~* 25 childs with urinary sample, Circadian rhythms assessed with actometer
Study: NCT01442116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stress echocardiography
Description: safety and efficacy of stress echocardiography
Study: NCT01255852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
Study: NCT03531788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armon Ayura (Kinova)
Description: Actively assisted mechanical arm support (electric powered to balance arm)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JAECO Wrex
Description: Passive mechanical arm support (elastic bands to balance arm)
Study: NCT00529451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: comparator
Study: NCT03732651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alteration of PaCO2 level
Description: step changes between 30, 40 and 50 mmHg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: alteration of PaCO2 level
Description: step changes between 30, 40 and 50 mmHg
Study: NCT02030405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given orally (PO)
Study: NCT02486809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Description: Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
Study: NCT03645265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory
Description: Use of auditory cues to improve speech production

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gestures
Description: Use of gestures to improve speech production